GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Silence Therapeutics PLC (NAS:SLN) » Definitions » FFO per Share

SLN (Silence Therapeutics) FFO per Share


View and export this data going back to 2020. Start your Free Trial

What is Silence Therapeutics FFO per Share?

FFO per Share only applies to REITs.


Silence Therapeutics Business Description

Traded in Other Exchanges
Address
72 Hammersmith Road, London, GBR, W14 8TH
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.